Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
Key PointsModerna has made progress with two important products this year.
Moderna's stock has seen a remarkable resurgence in 2023, with shares up 402% year-to-date, thanks to significant clinical and regulatory progress. The company announced on August 5 that the U.S. Food and Drug Administration (FDA) had approved mFLUSIVA, a flu vaccine that demonstrated greater efficacy than marketed flu vaccines in clinical trials.
This approval addresses an unmet need in the market, where current flu vaccines have efficacy rates ranging between 40% to 60% during the flu season. As Moderna continues to advance its mRNA vaccine platform, there may be further upside for the stock.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
